# TRUXIMA® (rituximab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rituximab

> TRUXIMA® (rituximab), sponsored by BRISTOL MYERS SQUIBB CO (BMY), received a complete response letter from the FDA; the decision is dated Sep 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TRUXIMA® (rituximab) |
| Codes |  |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | class iii or iv ln in august 2023, 2l relapsed/refractory dlbcl, class iii or class iv ln in august 2023, [Lymphoma](https://sec-api.dev/indications/lymphoma) |
| Modality | antibody |
| FDA designations | breakthrough, fast track, orphan, rmat |

## Timeline

### Aug 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: class III or IV LN in August 2023.
- First seen 2025-03-24, last confirmed 2026-03-10.
- SEC Form 10-K (accession 0000950170-25-043837): "6 clinical trial in patients with class III or IV LN in August 2023, and we dosed the first patient in this trial in April 2024." https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm
- SEC Form 10-K (accession 0001193125-26-100135): "Specifically, the FDA cleared our IND for AlloNK in combination with rituximab for our Phase 1/1b clinical trial in patients with class III or IV LN in August 2023, and we dosed the first patient in this trial in April 2024." https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm
- SEC Form 10-K (accession 0000950170-25-043837): "The FDA cleared our IND for AlloNK in combination with rituximab for our Phase 1/1b clinical trial in patients with class III or class IV LN in August 2023, and we dosed the first patient in this trial in April 2024." https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm

### 1H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2024-11-12, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0000950170-25-043837): "We expect to report initial data on autoimmune indications from at least one of our Phase 1/1b trial or the basket IIT in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-125382): "We expect to report initial data on autoimmune indications from at least one of our Phase 1/1b trial or the basket IIT in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1817241/000095017024125382/artv-20240930.htm

### Aug 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-05-08, last confirmed 2026-05-08.
- SEC prospectus (424B) (accession 0001193125-26-214706): "In addition, we announced that, following Investigational New Drug application clearance by the U.S. Food and Drug Administration (FDA), we have initiated a global Phase 2a company-sponsored basket clinical trial for AlloNK in combination with rituximab for refractory rheumatoid arthritis (RA), Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis, with site initiation and enrollment underway, which we believe is the first company-sponsored trial exploring an allogeneic cell therapy in refractory RA and Sjögren's disease in the U.S. In August 2025, we announced that we treated the first patient in the Phase 2a basket trial." https://www.sec.gov/Archives/edgar/data/1817241/000119312526214706/d119010d424b5.htm

### Sep 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2026-01-21, last confirmed 2026-01-21.
- Press release filed with the SEC (EX-99) (accession 0001575872-26-000034): "Received a CRL for rituximab biosimilar BLA, in reference to the ongoing resolution of observations arising from the Pre Approval Inspection (PAI) of our Biologics facility at Bachupally, Hyderabad, Telangana, India conducted in September 2025, as well as certain aspects pertaining to the BLA." https://www.sec.gov/Archives/edgar/data/1135951/000157587226000034/rdy0840_ex99-1.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-12-15, last confirmed 2025-12-15.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-318469): "First and Only Approved Therapy in SPS and CAR T for Autoimmune First completed registration-enabling trial in autoimmune CAR T Miv-cel achieved highly statistically significant benefit on primary and all secondary efficacy endpoints, durable clinical improvement and reversed disability scores 100% elimination of off-label immunotherapies with a single dose Well-tolerated and manageable safety profile Data supports expected SPS BLA submission for miv-cel in 1H 2026 BLA, biologics license application; CAR, chimeric antigen receptor. ©2025 Kyverna Therapeutics, Inc. 22 Immunotherapy defined as off-label immunosuppressants (e.g., prednisone), rituximab and/or intravenous immunoglobulin." https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/d33692dex991.htm

### Mar 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: 2L relapsed/refractory DLBCL.
- First seen 2026-07-30, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-088458): "Initiated China Phase III study in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with 2L relapsed/refractory DLBCL versus placebo in combination with R-GemOx in March 2026 (NCT07409428)." https://www.sec.gov/Archives/edgar/data/1648257/000110465926088458/hcm-20260730xex99d1.htm

### May 8, 2026: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-05-08, last confirmed 2026-08-06.
- SEC Form 10-Q (accession 0001193125-26-338029): "On May 8, 2026, we announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab." https://www.sec.gov/Archives/edgar/data/1817241/000119312526338029/artv-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-213242): "On May 8, 2026, we announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab." https://www.sec.gov/Archives/edgar/data/1817241/000119312526213242/artv-20260331.htm
- SEC prospectus (424B) (accession 0001193125-26-214706): "On May 8, 2026, we announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab." https://www.sec.gov/Archives/edgar/data/1817241/000119312526214706/d119010d424b5.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-05-08, last confirmed 2026-05-08.
- SEC Form 8-K (accession 0001193125-26-213239): "The Company expects to initiate the registrational trial in the second half of 2026 and report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029." https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-213239): "Artiva expects to initiate the registrational trial in the second half of 2026 and report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029." https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-213239): "In the second half of 2026, Artiva plans to initiate a Phase 3 randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 RA patients who have had an inadequate response to two or more biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) of distinct classes, with ACR50 response at six months as the primary efficacy endpoint." https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160dex991.htm

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-06-03, last confirmed 2026-06-24.
- Press release filed with the SEC (EX-99) (accession 0000950103-26-009416): "ADC Therapeutics expects to submit an sBLA in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_ex9901.htm
- SEC Form 8-K (accession 0000950103-26-008465): "in August and is preparing for a planned sBLA submission in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950103-26-008465): ""We intend to conduct a pre-sBLA meeting in August and are preparing for a planned sBLA submission in the fourth quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_9901.htm

### Oct 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2026-11-03, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001551152-26-000037): "•In October 2026, AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration Epkinly in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with DLBCL." https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/abbv-20260930.htm

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07015242 (A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-09 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." https://clinicaltrials.gov/study/NCT07015242

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07015242 (A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-09 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." https://clinicaltrials.gov/study/NCT07015242

Calendar months: [January 2028](https://sec-api.dev/fda-calendar/2028-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rituximab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TRUXIMA® (rituximab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rituximab

```bibtex
@misc{secapidev_pdufa_rituximab_20261116,
  title        = {TRUXIMA® (rituximab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rituximab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rituximab_20261116","title":"TRUXIMA® (rituximab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rituximab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
